Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 37

Cited In for PubMed (Select 8948338)

1.

Clinical prognostic factors of adjuvant radiation therapy for low-grade gliomas: results of 10 years survival.

Kaya V, Aksu MG, Korcum AF, Ozdemir B, Ceçen Y, Sindir B, Genç M.

Int J Clin Exp Med. 2014 May 15;7(5):1336-43. eCollection 2014.

2.

Peritumoral epilepsy: relating form and function for surgical success.

Cowie CJ, Cunningham MO.

Epilepsy Behav. 2014 Sep;38:53-61. doi: 10.1016/j.yebeh.2014.05.009. Epub 2014 Jun 2.

3.

Effect of the addition of chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: secondary analysis of RTOG 98-02.

Prabhu RS, Won M, Shaw EG, Hu C, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP.

J Clin Oncol. 2014 Feb 20;32(6):535-41. doi: 10.1200/JCO.2013.53.1830. Epub 2014 Jan 13.

4.

Long-term follow-up in adult patients with low-grade glioma (WHO II) postoperatively irradiated. Analysis of prognostic factors.

Mucha-Małecka A, Gliński B, Hetnał M, Jarosz M, Urbański J, Frączek-Błachut B, Dymek P, Małecki K, Chrostowska A.

Rep Pract Oncol Radiother. 2012 Feb 10;17(3):141-5. doi: 10.1016/j.rpor.2012.01.007. eCollection 2012.

5.

Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop.

Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S.

Neuro Oncol. 2014 Jan;16(2):173-8. doi: 10.1093/neuonc/not229. Epub 2013 Dec 4. Review.

6.

Stereotactic iodine-125 brachytherapy for the treatment of WHO grades II and III gliomas located in the central sulcus region.

Ruge MI, Kickingereder P, Grau S, Dorn F, Galldiks N, Treuer H, Sturm V.

Neuro Oncol. 2013 Dec;15(12):1721-31. doi: 10.1093/neuonc/not126. Epub 2013 Sep 17.

7.

Central nervous system cancers.

Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Maor MH, Moots PL, Morrison T, Mrugala MM, Newton HB, Portnow J, Raizer JJ, Recht L, Shrieve DC, Sills AK Jr, Tran D, Tran N, Vrionis FD, Wen PY, McMillian N, Ho M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1114-51.

8.

Current treatment of low grade gliomas.

van den Bent MJ, Snijders TJ, Bromberg JE.

Memo. 2012 Sep;5(3):223-227. Epub 2012 Jun 5.

9.

Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.

Youland RS, Schomas DA, Brown PD, Nwachukwu C, Buckner JC, Giannini C, Parney IF, Laack NN.

Neuro Oncol. 2013 Aug;15(8):1102-10. doi: 10.1093/neuonc/not080. Epub 2013 Jun 27.

10.

Integration of epidemiology, immunobiology, and translational research for brain tumors.

Okada H, Scheurer ME, Sarkar SN, Bondy ML.

Ann N Y Acad Sci. 2013 May;1284:17-23. doi: 10.1111/nyas.12115.

11.

Response to postoperative radiotherapy as a prognostic factor for patients with low-grade gliomas.

Spych M, Gottwald L, Jesień-Lewandowicz E, Sztajer S, Fijuth J.

Oncol Lett. 2012 Sep;4(3):455-460. Epub 2012 Jun 14.

12.

Adult low-grade glioma: 19-year experience at a single institution.

Youland RS, Brown PD, Giannini C, Parney IF, Uhm JH, Laack NN.

Am J Clin Oncol. 2013 Dec;36(6):612-9. doi: 10.1097/COC.0b013e31825d580a.

13.

Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802.

Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ, Barger GR, Brown PD, Gilbert MR, Mehta MP.

J Clin Oncol. 2012 Sep 1;30(25):3065-70. doi: 10.1200/JCO.2011.35.8598. Epub 2012 Jul 30.

14.

Relative survival of patients with supratentorial low-grade gliomas.

Smoll NR, Gautschi OP, Schatlo B, Schaller K, Weber DC.

Neuro Oncol. 2012 Aug;14(8):1062-9. doi: 10.1093/neuonc/nos144. Epub 2012 Jul 6.

15.

Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas.

Pallud J, Llitjos JF, Dhermain F, Varlet P, Dezamis E, Devaux B, Souillard-Scémama R, Sanai N, Koziak M, Page P, Schlienger M, Daumas-Duport C, Meder JF, Oppenheim C, Roux FX.

Neuro Oncol. 2012 Apr;14(4):496-505. doi: 10.1093/neuonc/nos069. Epub 2012 Mar 13.

16.

Recent advancements in multimodality treatment of gliomas.

Hadziahmetovic M, Shirai K, Chakravarti A.

Future Oncol. 2011 Oct;7(10):1169-83. doi: 10.2217/fon.11.102. Review.

17.

Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection.

Suchorska B, Ruge M, Treuer H, Sturm V, Voges J.

Neuro Oncol. 2011 Oct;13(10):1133-42. doi: 10.1093/neuonc/nor100. Epub 2011 Aug 25.

18.

The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II.

Smits A, Baumert BG.

Int J Mol Imaging. 2011;2011:372509. doi: 10.1155/2011/372509. Epub 2011 Apr 28.

19.

Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51.

Daniels TB, Brown PD, Felten SJ, Wu W, Buckner JC, Arusell RM, Curran WJ, Abrams RA, Schiff D, Shaw EG.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):218-24. doi: 10.1016/j.ijrobp.2010.05.003. Epub 2011 May 5.

20.

First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.

Taal W, Dubbink HJ, Zonnenberg CB, Zonnenberg BA, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Kros JM, Kouwenhoven MC, van Marion R, van Heuvel I, van der Holt B, Bromberg JE, Sillevis Smitt PA, Dinjens WN, van den Bent MJ; Dutch Society for Neuro-Oncology.

Neuro Oncol. 2011 Feb;13(2):235-41. doi: 10.1093/neuonc/noq177. Epub 2010 Dec 21.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk